Shanghai Generon to Start US Trial of GvHD Biologic Drug
May 04, 2015 at 06:23 AM EDT
Shanghai Generon Corporation has been granted FDA approval to begin a US Phase IIa clinical trial of its novel recombinant human interleukin. The molecule will be tested as a treatment for graft-versus-host disease in the lower intestines of patients undergoing hematopoietic stem cell transplants, a side-effect with incidence as high as 50%. Generon says the drug offers a treatment alternative that, instead of increasing immune suppression, aims to regenerate the intestines. More details.... Share this with colleagues: // //